Emerging therapeutics for chronic hepatitis B

Mark E Mailliard, John L. Gollan

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Hepatitis B is a global health problem. Patients with chronic hepatitis B (CHB) carry a significant risk to eventually develop cirrhotic liver disease. Recent therapeutic advances against CHB offer excellent potential for long-term suppression of hepatitis B virus (HBV) replication during antiviral therapy, and occasionally a durable remission off medication. Selection of appropriate patients for antiviral therapy depends on identification of HBV replication and an elevated alanine aminotransferase level or histologic liver injury. Pegylated interferon alpha offers potent immunomodulatory and antiviral activity with the potential for durability, but also with adverse effects and significant cost. The nucleoside or nucleotide analogs, lamivudine, adefovir, and entecavir, suppress HBV replication and are extremely well-tolerated, but long-term or even lifelong therapy is required. Most experience has been gained with lamivudine, but viral resistance occurs frequently. Newer analogs appear to be relatively free of this problem. Approaches using a combination of agents have promise, but have yet to be proven superior to individual drugs alone.

Original languageEnglish (US)
Pages (from-to)155-166
Number of pages12
JournalAnnual Review of Medicine
Volume57
DOIs
StatePublished - Feb 24 2006

Fingerprint

Chronic Hepatitis B
Viruses
Antiviral Agents
Lamivudine
Virus Replication
Hepatitis B virus
Liver
Medical problems
Alanine Transaminase
Nucleosides
Interferon-alpha
Durability
Therapeutics
Nucleotides
Hepatitis B
Patient Selection
Liver Diseases
Costs and Cost Analysis
Pharmaceutical Preparations
Costs

Keywords

  • Adefovir
  • Entecavir
  • Interferon alpha
  • Lamivudine
  • Nucleoside analogs

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Emerging therapeutics for chronic hepatitis B. / Mailliard, Mark E; Gollan, John L.

In: Annual Review of Medicine, Vol. 57, 24.02.2006, p. 155-166.

Research output: Contribution to journalReview article

@article{d8e576d0360d490cb41148d6cc9bfead,
title = "Emerging therapeutics for chronic hepatitis B",
abstract = "Hepatitis B is a global health problem. Patients with chronic hepatitis B (CHB) carry a significant risk to eventually develop cirrhotic liver disease. Recent therapeutic advances against CHB offer excellent potential for long-term suppression of hepatitis B virus (HBV) replication during antiviral therapy, and occasionally a durable remission off medication. Selection of appropriate patients for antiviral therapy depends on identification of HBV replication and an elevated alanine aminotransferase level or histologic liver injury. Pegylated interferon alpha offers potent immunomodulatory and antiviral activity with the potential for durability, but also with adverse effects and significant cost. The nucleoside or nucleotide analogs, lamivudine, adefovir, and entecavir, suppress HBV replication and are extremely well-tolerated, but long-term or even lifelong therapy is required. Most experience has been gained with lamivudine, but viral resistance occurs frequently. Newer analogs appear to be relatively free of this problem. Approaches using a combination of agents have promise, but have yet to be proven superior to individual drugs alone.",
keywords = "Adefovir, Entecavir, Interferon alpha, Lamivudine, Nucleoside analogs",
author = "Mailliard, {Mark E} and Gollan, {John L.}",
year = "2006",
month = "2",
day = "24",
doi = "10.1146/annurev.med.57.121304.131422",
language = "English (US)",
volume = "57",
pages = "155--166",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Emerging therapeutics for chronic hepatitis B

AU - Mailliard, Mark E

AU - Gollan, John L.

PY - 2006/2/24

Y1 - 2006/2/24

N2 - Hepatitis B is a global health problem. Patients with chronic hepatitis B (CHB) carry a significant risk to eventually develop cirrhotic liver disease. Recent therapeutic advances against CHB offer excellent potential for long-term suppression of hepatitis B virus (HBV) replication during antiviral therapy, and occasionally a durable remission off medication. Selection of appropriate patients for antiviral therapy depends on identification of HBV replication and an elevated alanine aminotransferase level or histologic liver injury. Pegylated interferon alpha offers potent immunomodulatory and antiviral activity with the potential for durability, but also with adverse effects and significant cost. The nucleoside or nucleotide analogs, lamivudine, adefovir, and entecavir, suppress HBV replication and are extremely well-tolerated, but long-term or even lifelong therapy is required. Most experience has been gained with lamivudine, but viral resistance occurs frequently. Newer analogs appear to be relatively free of this problem. Approaches using a combination of agents have promise, but have yet to be proven superior to individual drugs alone.

AB - Hepatitis B is a global health problem. Patients with chronic hepatitis B (CHB) carry a significant risk to eventually develop cirrhotic liver disease. Recent therapeutic advances against CHB offer excellent potential for long-term suppression of hepatitis B virus (HBV) replication during antiviral therapy, and occasionally a durable remission off medication. Selection of appropriate patients for antiviral therapy depends on identification of HBV replication and an elevated alanine aminotransferase level or histologic liver injury. Pegylated interferon alpha offers potent immunomodulatory and antiviral activity with the potential for durability, but also with adverse effects and significant cost. The nucleoside or nucleotide analogs, lamivudine, adefovir, and entecavir, suppress HBV replication and are extremely well-tolerated, but long-term or even lifelong therapy is required. Most experience has been gained with lamivudine, but viral resistance occurs frequently. Newer analogs appear to be relatively free of this problem. Approaches using a combination of agents have promise, but have yet to be proven superior to individual drugs alone.

KW - Adefovir

KW - Entecavir

KW - Interferon alpha

KW - Lamivudine

KW - Nucleoside analogs

UR - http://www.scopus.com/inward/record.url?scp=32944475449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944475449&partnerID=8YFLogxK

U2 - 10.1146/annurev.med.57.121304.131422

DO - 10.1146/annurev.med.57.121304.131422

M3 - Review article

C2 - 16409142

AN - SCOPUS:32944475449

VL - 57

SP - 155

EP - 166

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -